Sponsor

H e x a l AG

Germany Industriestrasse 25, 83607, Germany

About the sponsor

H e x a l AG supports clinical research in advanced and resected melanoma, including adjuvant treatment settings for stage IIB, IIC, and III disease, with a strong focus on pembrolizumab- and nivolumab-related biosimilar development.

Advanced unresectable or metastatic melanoma
Resected stage IIB, IIC, or III melanoma
Adjuvant therapy in skin cancer

These studies reflect interest in immune checkpoint inhibition within both metastatic and earlier-stage oncology care.

About Specializations

H e x a l AG runs clinical trials in conditions such as Non-small cell lung cancer, Malignant melanoma stage III, Malignant melanoma stage II, among others.

All trials